Hansoh Pharma reports strong revenue and profit growth in first half of 2025

For the six months ended June 30, 2025, Hansoh Pharmaceutical Group reported a 14.3% increase in revenue, reaching approximately 7.43bn yuan, with profit growing by 15.0% to 3.13bn yuan. Basic earnings per share rose by 14.8% to 0.53 yuan. Innovative drugs and collaborative products were key drivers, contributing approximately 6.14bn yuan, representing 82.7% of total revenue and a 22.1% increase year-on-year. R&D expenditure for the period was approximately 1.44bn yuan, accounting for 19.4% of revenue.

The group continued its robust R&D efforts, with over 70 clinical trials for innovative drugs and over 40 drug candidates under investigation. Significant milestones included FDA Breakthrough Therapy Designation for GSK5764227 (HS-20093) in osteosarcoma, NMPA Priority Review for XINYUE (Inebilizumab Injection) in IgG4-RD, and multiple new indications approved for Ameile (Aumolertinib Mesilate Tablets) in NSCLC. The company also secured an exclusive worldwide license (excluding Chinese Mainland, Hong Kong, and Macau) to Regeneron for HS-20094, with an upfront payment of $80m and potential milestones of up to $1.93bn.

In August 2025, the company completed a placing of 108,000,000 ordinary shares at HK$36.30 per share, raising approximately HK$3.89bn in net proceeds, earmarked primarily for R&D, new production facilities, and working capital. The board declared an interim dividend of HK$23.16 cents per share for the period.